Viridian Therapeutics, Inc.(VRDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VRDN Viridian Therapeutics, Inc.

Market Closed 11-06 16:00:00 EST

28.49

-0.06

-0.21%

盘后28.48

-0.01-0.04%

19:52 EST

High29.47	Low27.86	Vol4.50M
Open28.66	D1 Closing28.55	Amplitude5.64%
Mkt Cap3.23B	Tradable Cap2.88B	Total Shares113.29M
T/O128.32M	T/O Rate4.46%	Tradable Shares101.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VRDN","market":"US","secType":"STK","nameCN":"Viridian Therapeutics, Inc.","latestPrice":28.49,"timestamp":1793998800000,"preClose":28.55,"halted":0,"volume":4501358,"hourTrading":{"tag":"盘后","latestPrice":28.48,"preClose":28.49,"latestTime":"19:52 EST","volume":157413,"amount":4502014.575,"timestamp":1794012766525,"change":-0.01,"changeRate":-0.000351,"amplitude":0.037206},"delay":0,"changeRate":-0.002101576182136682,"floatShares":101000000,"shares":113292269,"eps":-3.994278,"marketStatus":"Market Closed","change":-0.06,"latestTime":"11-06 16:00:00 EST","open":28.66,"high":29.47,"low":27.86,"amount":128322220.111668,"amplitude":0.056392,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.994278,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":28.55,"preHourTrading":{"tag":"盘前","latestPrice":28.71,"preClose":28.55,"latestTime":"09:29 EST","volume":2723,"amount":78889.862856,"timestamp":1793975399999,"change":0.16,"changeRate":0.005604,"amplitude":0.010508},"postHourTrading":{"tag":"盘后","latestPrice":28.48,"preClose":28.49,"latestTime":"19:52 EST","volume":157413,"amount":4502014.575,"timestamp":1794012766525,"change":-0.01,"changeRate":-0.000351,"amplitude":0.037206},"volumeRatio":0.9464605799256287,"impliedVol":1.0244,"impliedVolPercentile":0.6773},"requestUrl":"/m/hq/s/VRDN/wiki","defaultTab":"wiki","newsList":[{"id":"2681014671","title":"Viridian Therapeutics, Inc. : Needham Raises Target Price to $38 from $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2681014671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681014671?lang=en_us&edition=fundamental","pubTime":"2026-11-05 13:37","pubTimestamp":1793857070,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nFWN46M0H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680006841","title":"Viridian Therapeutics, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2680006841","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680006841?lang=en_us&edition=fundamental","pubTime":"2026-11-04 23:12","pubTimestamp":1793805141,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings SummaryViridian Therapeutics, Inc.VRDN.OQreported a quarterly adjusted loss of 81 cents per share for the quar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL5N46L2CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680051270","title":"Viridian Therapeutics Expects Cash, Anticipated Revenue to Fund Business Plans Through Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2680051270","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680051270?lang=en_us&edition=fundamental","pubTime":"2026-11-04 21:10","pubTimestamp":1793797809,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics Expects Cash, Anticipated Revenue to Fund Business Plans Through ProfitabilityViridian Therapeutics expects current cash and anticipated revenues to fund its current business pla","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL8D1Fym:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680805612","title":"Viridian Posts First Lumvoa Revenue but Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2680805612","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680805612?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:27","pubTimestamp":1793795254,"startTime":"0","endTime":"0","summary":"Viridian posts first Lumvoa revenue but net loss widensOverviewU.S. biotech firm reported first net product revenue from Lumvoa after TED launch in Q3Q3 net loss widened to $101.2 mln from $34.6 mln a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4585","BK4556","LU1861558580.USD","LU1861559042.SGD","VRDN","BK4535","BK4139","BK4588","BK4007","ARVN","BK4505","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680623056","title":"Earnings Flash (VRDN) Viridian Therapeutics Posts Q3 Net Loss $0.81 a Share, vs. FactSet Est of $1.00 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2680623056","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680623056?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:19","pubTimestamp":1793794780,"startTime":"0","endTime":"0","summary":"Earnings Flash (VRDN) Viridian Therapeutics Posts Q3 Net Loss $0.81 a Share, vs. FactSet Est of $1.00 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680055766","title":"Viridian Therapeutics Q3 Net Loss More than Doubles to $101.21 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2680055766","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680055766?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:12","pubTimestamp":1793794365,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics Q3 net loss more than doubles to $101.21 millionViridian Therapeutics’ third-quarter 2026 net loss more than doubled year over year to $101.21 million.Total revenues fell 64% yea","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL6KJsWd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680055880","title":"Press Release: Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2680055880","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680055880?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:01","pubTimestamp":1793793660,"startTime":"0","endTime":"0","summary":"--  Lumvoa generated $24.7 million in net product revenue;--  More than 100 patients on therapy with Lumvoa;--  Significant market access progress made during the quarter;--  CMS has assigned Lumvoa a permanent J-code J3242, effective. --  Continued execution across field sales, medical, market access,--  Elegrobart: BLA submission on track for Q1 2027. --  Viridian anticipates launching elegrobart, if approved, in a. --  The Lumvoa Commercial and Medical infrastructure is expected to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BLA.AU","LENZ","LU2065732104.USD","PRGS","03160","BK4588","BK4097","TM","BK4099","VRDN","BK4604","TSHR","BK4539","BK4585","BK4555","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680670027","title":"Analysts’ Top Healthcare Picks: Viridian Therapeutics (VRDN), Idexx Laboratories (IDXX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680670027","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680670027?lang=en_us&edition=fundamental","pubTime":"2026-11-04 10:30","pubTimestamp":1793759418,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viridian Therapeutics (VRDN) and Idexx Laboratories ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-viridian-therapeutics-vrdn-idexx-laboratories-idxx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-viridian-therapeutics-vrdn-idexx-laboratories-idxx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRDN","GB00B4QBRK32.GBP","LU0128526141.USD","LABU","LU2404859667.USD","HCSG","BK4585","LU1291159041.SGD","LU0170899867.USD","XBI","LU0345774631.USD","BK4082","LU0690374615.EUR","XLV","BK4139","BK4137","BK4567","LU1941712264.USD","LU0690374961.EUR","BK4588","LU2404859741.USD","LU1941712348.USD","BK4581","LU1989771016.USD","GB00B4LPDJ14.GBP","LU0029874061.USD","PAWZ","IDXX","LU0345774391.USD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680779579","title":"Learn Why The Bull Case For Viridian Therapeutics Stock Could Change Following FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2680779579","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680779579?lang=en_us&edition=fundamental","pubTime":"2026-11-04 01:23","pubTimestamp":1793726625,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics secured FDA approval in June 2026 for Lumvoa to treat both active and chronic thyroid eye disease, and moved straight into commercial launch in the United States.\nThe approval gives Viridian Therapeutics its first marketed IGF-1R therapy in a roughly US$2b thyroid eye disease market that currently appears only lightly penetrated by this drug class.\nWe will look at how Viridian Therapeutics' investment narrative evolves as Lumvoa's rapid FDA approval and launch reshape...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/learn-why-the-bull-case-for-viridian-therapeutics-stock-coul","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/learn-why-the-bull-case-for-viridian-therapeutics-stock-coul","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK4539","LENZ","BK4007","BK4588","BK4585","BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102058326","title":"Earning Preview: Viridian Therapeutics, Inc. this quarter’s revenue is expected to increase by 14,755.18%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1102058326","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102058326?lang=en_us&edition=fundamental","pubTime":"2026-10-29 00:46","pubTimestamp":1793205997,"startTime":"0","endTime":"0","summary":"Abstract Viridian Therapeutics, Inc. will report its quarterly results on November 04, 2026 Pre-MKt, with current models pointing to revenue around 5.04 million US dollars, adjusted EPS near -0.91,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Viridian Therapeutics, Inc. this quarter’s revenue is expected to increase by 14,755.18%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677676823","title":"Analyst Forecasts Just Became More Bearish On Viridian Therapeutics, Inc. (NASDAQ:VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2677676823","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677676823?lang=en_us&edition=fundamental","pubTime":"2026-10-21 19:01","pubTimestamp":1792580510,"startTime":"0","endTime":"0","summary":"Market forces rained on the parade of Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) shareholders today, when the analysts...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/analyst-forecasts-just-became-more-bearish-on-viridian-thera","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/analyst-forecasts-just-became-more-bearish-on-viridian-thera","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSQ","JEPQ","TECS","NDX","FTEC","03086","IYW","QQQ","NVIW.SI","TQQY","QLD","QDTE","SQQQ","BK4139","QYLG","MNQmain","QID","QQQJ","VRDN","ONEQ","NQmain","TQQQ",".IXIC","QQQM","GPIQ","QQQA","QQQE","QQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677616302","title":"Viridian Therapeutics Schedules Third-Quarter Financial Results Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2677616302","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677616302?lang=en_us&edition=fundamental","pubTime":"2026-10-21 04:00","pubTimestamp":1792526430,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics Schedules Third-Quarter Financial Results ReleaseViridian Therapeutics will report third-quarter 2026 financial results before the market opens on November 4, 2026.Management wil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261020:nNDL9RtGBb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674882333","title":"RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674882333","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674882333?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:48","pubTimestamp":1791510481,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Lisa Walter from RBC Capital maintained a Buy rating on Viridian Therapeutics, with a price target of $38.00. Walte...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672742406","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2672742406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672742406?lang=en_us&edition=fundamental","pubTime":"2026-10-03 09:50","pubTimestamp":1790992231,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insulet (PODD) and Viridian Therapeutics (VRDN) with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-369?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-369?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU2065171311.SGD","XLV","LU2065170008.USD","HCSG","LU2065171402.SGD","LU2324357040.USD","BK4139","BK4588","BK4566","VRDN","BK4082","BK4551","BK4581","LU0029874061.USD","LU1261432733.SGD","XBI","LU0728928796.USD","BK4585","LU1119994496.HKD","PODD","LU1084165304.USD","LU2065169927.USD","LU0128526141.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669072123","title":"Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669072123","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669072123?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:45","pubTimestamp":1790091902,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics'  Lumvoa is off to a \"stronger start\" than anticipated, RBC Capital Markets said in a Tuesday note.RBC analysts talked with six key opinion leaders about the drug, which treats Thyroid Eye Disease, and discovered that it has had good early uptake so far. Half of the doctors have written at least one prescription for the drug since its launch on June 26, and a third have reported infusing at least one patient, the analysts noted.The evidence of early adoption suggests that physicians are enthusiastic about gaining experience with Lumvoa and seeing how it stacks up against competing treatment Tepezza on efficacy and safety, the analysts said.Rather than clinical reluctance, the main headwind for Lumvoa in the near term is challenges with access; a permanent J-code to avoid insurance delays still is to come and there have been formulary delays at academic centers, according to the note.RBC reiterated the company's stock rating at outperform, speculative risk, and rai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","VRDN","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669149323","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669149323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669149323?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:10","pubTimestamp":1790075417,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-cvrx-cvrx-butterfly-network-bfly-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-cvrx-cvrx-butterfly-network-bfly-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0029874061.USD","VRDN","CVRX","BK4539","BK4581","BK4585","LABU","LU0128526141.USD","BFLY","HCSG","XLV","BK4139","BK4137","BK4082","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669102351","title":"Viridian Therapeutics, Inc. : RBC Raises Target Price to $38 from $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2669102351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669102351?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:24","pubTimestamp":1790069041,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E02I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607925","title":"Sling Therapeutics Raises $123 Million to Advance Thyroid Eye Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607925","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607925?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556400,"startTime":"0","endTime":"0","summary":"Sling Therapeutics raises $123 million to advance thyroid eye disease drugSept 16 (Reuters)-Drug developer Sling Therapeutics said on Wednesday ithad raised $123 million to advance a late-stage trial ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nL4N457178:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","IE00BFTCPJ56.SGD","BK4533","LU0320765992.SGD","PJP","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU2242652126.USD","IBB","LU2468319806.SGD","LU1061106388.HKD","AMGN","LU2089984988.USD","PBE","BK4581","BK4588","IE0009355771.USD","LU0289739699.SGD","TBXU","BK4566","LU0058720904.USD","LU1571399168.USD","LU1057294990.SGD","IE00B2B36J28.USD","LU0889565916.HKD","LU2242646821.SGD","VRDN","BIB","BK4139","LU0122379950.USD","BK4599","IBBQ","BBH","IE00BJJMRZ35.SGD","LU2112291526.USD","LU0109394709.USD","LU0868494617.USD","SG9999001440.SGD","LU1023059063.AUD","IE0002141913.USD","BK4585","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664846084","title":"Viridian Therapeutics Joins Wells Fargo Annual Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664846084","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664846084?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:00","pubTimestamp":1788379255,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics joins Wells Fargo annual healthcare conference fireside chatViridian Therapeutics management will join a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8, 2026.Session is scheduled for 12:45 p.m. ET.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on September 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL6p97r2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859516","title":"Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Teladoc (TDOC) and Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859516?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:10","pubTimestamp":1788264606,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viridian Therapeutics (VRDN), Teladoc (TDOC) and P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viridian-therapeutics-vrdn-teladoc-tdoc-and-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viridian-therapeutics-vrdn-teladoc-tdoc-and-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","BK4137","XBI","TDOC","BK4504","BK4588","BK4139","BK4585","BK4567","BK4581","LU0029874061.USD","LU0128526141.USD","HCSG","VRDN","LU1861558580.USD","PTGX","LABU","BK4548","BK4534","XLV","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.viridiantherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1548},{"period":"1month","weight":0.5585},{"period":"3month","weight":0.2077},{"period":"6month","weight":0.7152},{"period":"1year","weight":0.036},{"period":"ytd","weight":-0.0845}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.269131},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.083186},{"month":3,"riseRate":0.25,"avgChangeRate":-0.101161},{"month":4,"riseRate":0.583333,"avgChangeRate":0.000279},{"month":5,"riseRate":0.333333,"avgChangeRate":0.008151},{"month":6,"riseRate":0.583333,"avgChangeRate":0.009034},{"month":7,"riseRate":0.538462,"avgChangeRate":0.011548},{"month":8,"riseRate":0.230769,"avgChangeRate":-0.059066},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.020088},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.022696},{"month":11,"riseRate":0.615385,"avgChangeRate":0.157069},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.069844}],"exchange":"NASDAQ","name":"Viridian Therapeutics, Inc.","nameEN":"Viridian Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viridian Therapeutics, Inc.(VRDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Viridian Therapeutics, Inc.(VRDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Viridian Therapeutics, Inc.,VRDN,Viridian Therapeutics, Inc.股票,Viridian Therapeutics, Inc.股票老虎,Viridian Therapeutics, Inc.股票老虎国际,Viridian Therapeutics, Inc.行情,Viridian Therapeutics, Inc.股票行情,Viridian Therapeutics, Inc.股价,Viridian Therapeutics, Inc.股市,Viridian Therapeutics, Inc.股票价格,Viridian Therapeutics, Inc.股票交易,Viridian Therapeutics, Inc.股票购买,Viridian Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viridian Therapeutics, Inc.(VRDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Viridian Therapeutics, Inc.(VRDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}